Gheorghita Stela, Birca Ludmila, Donos Ala, Wasley Annemarie, Birca Ion, Cojocaru Radu, Melnick Anatol, Ciobanu Silviu, Mosina Liudmila, Cortese Margaret M, Parashar Umesh D, Lopman Ben
National Center for Public Health.
Chisinau City Infectious Diseases Hospital for Children.
Clin Infect Dis. 2016 May 1;62 Suppl 2(Suppl 2):S140-6. doi: 10.1093/cid/civ1209.
The Republic of Moldova was the first low- to middle-income country in the World Health Organization European Region to introduce rotavirus vaccine (July 2012). We aimed to assess the impact of the rotavirus vaccine program and estimate vaccine effectiveness (VE).
Surveillance for rotavirus gastroenteritis was conducted in 2 hospitals in the capital city of Chisinau starting in September 2009. Monthly rotavirus admissions by age were examined before and after introduction of rotavirus vaccination using interrupted time-series analyses. We performed a case-control study of VE by comparing rotavirus case patients with test-negative controls.
Coverage with at least 1 dose of vaccine increased from 35% in year 1 to 55% in year 2 for children <1 year of age. The percentage of hospital admissions positive for rotavirus fell from 45% in the prevaccine period to 25% (rate reduction, 36%; 95% confidence interval [CI], 26%-44%) and 14% (rate reduction, 67%; 95% CI, 48%-88%) in the first and second years after vaccine introduction, respectively, among children aged <5 years. Reductions were most pronounced among those aged <1 year. Significant reductions among cohorts too old to be vaccinated suggest indirect benefits. Two-dose VE was 79% (95% CI, 62%-88%) against rotavirus hospitalization and 84% (95% CI, 64%-93%) against moderate to severe rotavirus.
These results consistently point to profound direct and herd immunity impacts of the rotavirus vaccine program in young children in the Republic of Moldova. Vaccine coverage was modest in these early years following introduction, so there remains potential for further disease reductions.
摩尔多瓦共和国是世界卫生组织欧洲区域首个引入轮状病毒疫苗的低收入和中等收入国家(2012年7月)。我们旨在评估轮状病毒疫苗计划的影响并估计疫苗效力(VE)。
自2009年9月起,在首都基希讷乌的2家医院开展轮状病毒胃肠炎监测。采用中断时间序列分析方法,对引入轮状病毒疫苗前后各年龄段的轮状病毒住院病例进行月度检查。通过比较轮状病毒病例患者与检测阴性对照,开展了疫苗效力的病例对照研究。
1岁以下儿童至少接种1剂疫苗的覆盖率从第1年的35%增至第2年的55%。在引入疫苗后的第1年和第2年,5岁以下儿童中轮状病毒检测呈阳性的住院病例百分比分别从疫苗接种前的45%降至25%(降幅36%;95%置信区间[CI],26%-44%)和14%(降幅67%;95%CI,48%-88%)。1岁以下儿童的降幅最为显著。未到接种年龄的队列中也出现显著下降,表明存在间接益处。两剂疫苗针对轮状病毒住院的效力为79%(95%CI,62%-88%),针对中度至重度轮状病毒的效力为84%(95%CI,64%-93%)。
这些结果一致表明,轮状病毒疫苗计划对摩尔多瓦共和国幼儿产生了深远的直接和群体免疫影响。在引入疫苗后的最初几年,疫苗覆盖率适中,因此仍有进一步降低疾病发生率的潜力。